Patsnap
Singapore-anchored patent and R&D intelligence AI used by SEA pharma, biotech, and conglomerate R&D teams
Patsnap is a patent and R&D intelligence AI platform best for SEA pharma, biotech, materials, electronics, and conglomerate R&D teams with annual R&D budgets above USD 5M who need AI-driven patent search, freedom-to-operate analysis, and competitive R&D intelligence. Its SEA edge is Singapore HQ plus deep deployment in Asian patent offices - CNIPA, JPO, KIPO - which gives semantic search and litigation tracking quality that Clarivate Derwent lags on in Asia. The honest caveat: enterprise SaaS pricing at USD 1,200-18,000 per user per year makes it overkill for SEA SMEs and academics, who are usually fine with free Google Patents or Lens.org.
- ✓Strongest Asian patent office coverage including CNIPA, JPO, KIPO
- ✓AI-driven semantic search across 170 million global patents
- ✓Singapore HQ for SEA regional buyers on procurement
- ✓Chemistry and biosequence search modules for pharma and biotech
- ✓Customer logos include GSK, Roche, Honda, Subaru at enterprise scale
- ×Enterprise pricing rules out SEA SMEs and academic researchers
- ×Clarivate still wins on US/EU patent litigation database depth
- ×Modules like chemistry and litigation add cost on top of base subscription
- ×Custom partner commission with limited public transparency
About Patsnap
Patsnap is a Singapore- and Suzhou-headquartered patent and R&D intelligence AI SaaS used by SEA pharma, biotech, materials, electronics, and conglomerate R&D teams for patent search, technology scouting, IP litigation analysis, freedom-to-operate analysis, and competitive R&D intelligence. Used by GSK, Roche, Honda, Subaru, and major SEA conglomerates and R&D-driven enterprises.
Key Features
Best For
Southeast Asia Fit
Patsnap is the Singapore-anchored patent and R&D intelligence AI for SEA pharma, biotech, materials, and conglomerate R&D teams. Pricing is enterprise SaaS and typically lands at USD 1,200 to USD 18,000 per user per year depending on user count, modules (chemistry, biosequence, litigation), and contract term. For SEA pharma, biotech, and conglomerates with R&D budgets over USD 5 million annually, Patsnap's AI patent search and freedom-to-operate analysis pay back within two quarters on R&D efficiency and IP risk avoidance. Clarivate Derwent and Questel Orbit are competitive alternatives; Patsnap typically wins on Asian patent office (CNIPA, JPO, KIPO) deployment depth and on AI-driven semantic search quality, Clarivate wins on US/EU patent litigation databases. For SEA SMEs and academic researchers, Google Patents or free Lens.org are usually fine.
- Global
- SEA
- Singapore
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Hong Kong
Integrations
- Other
- REST API
- MCP Server
- UI Widgets
- Agent Skills
- Open Platform API
- Dev Sandbox
- Data APIs
- Cloud Deployment
- On-prem Deployment
We verify pricing and features via official vendor documentation and live platform audits. Software-listing.com is independent and may earn affiliate commissions from some links.
Related Analysis & Guides
The questions operators actually ask.
Is Patsnap the right pick for SEA pharma R&D teams?
Yes. Patsnap is the Singapore-anchored patent intelligence AI used by SEA pharma and biotech for scouting compounds and freedom-to-operate analysis. For R&D budgets above USD 5M annually, it typically pays back within two quarters on R&D efficiency and IP risk avoidance.
Should academic researchers use Patsnap?
No, not really. At USD 1,200-18,000 per user per year, Patsnap is enterprise-tier. Academic researchers are usually fine with free alternatives like Google Patents or Lens.org for typical literature and prior art searches.
How does Patsnap compare to Clarivate Derwent for SEA buyers?
It depends on use case. Patsnap typically wins on Asian patent office depth and AI-driven semantic search quality. Clarivate Derwent wins on US/EU patent litigation databases and traditional taxonomic search. SEA conglomerates with Asian R&D priorities usually shortlist Patsnap first.